Sabarni Sarker, Md. Ashraf Ali, R. Barman, Shuji Noguchi, Y. Iwao, S. Itai, M. I. I. Wahed
{"title":"硝苯地平负载固体脂质纳米颗粒在果糖诱导的糖尿病大鼠体内的制备及降糖作用","authors":"Sabarni Sarker, Md. Ashraf Ali, R. Barman, Shuji Noguchi, Y. Iwao, S. Itai, M. I. I. Wahed","doi":"10.4236/PP.2018.910035","DOIUrl":null,"url":null,"abstract":"The use of Nifedipine (NI), a dihydropyridine \ncalcium channel blocker, is limited due to its \npoor aqueous solubility. However, NI loaded solid-lipid nanoparticles (NI-SLN) \nare known to exhibit suitable pharmacokinetic properties and good \nbiocompatibility. The present investigation was designed to evaluate the \neffects of NI-SLN on glucose homeostasis, lipid metabolism and liver function \nin fructose-induced diabetic rats. NI-SLN was prepared by high pressure \nhomogenization technique followed by lyophilization with trehalose as \ncryoprotectant. Diabetes was induced into rats by the administration of \nfructose (10%) in drinking water for six weeks. After induction of diabetes, \nrats were divided into four groups for the oral ingestion of NI, NI-SLN and/or \nvehicles and their effects on blood glucose levels, oral glucose tolerance test \n(OGTT), lipid profile, biochemical parameters, electrolytes and histopathology \nwere observed. Single dose administration and treatment with NI-SLN showed \nsignificant glucose lowering efficacy in fructose-induced diabetic rats. \nAlthough NI and NI-SLN did not alter the fasting blood glucose level in normal \nrats, diabetic rats treated with NI-SLN resulted in significant reduction in \nglucose level for 24 hr. In OGTT, NI-SLN exhibited significant \nantihyperglycemic activity in both normal and diabetic rats. So, NI-SLN has \nbetter glucose lowering efficacy than that of pure NI in diabetic rats. The \nsurvival rates in rats among the treatment groups were 100%. Treatment with \nNI-SLN significantly improved lipid profiles than NI alone and the effect was \ndose-dependent. Administration of NI-SLN significantly reduced uric acid, \ncreatinine levels and maintained a good cationic balance. After two weeks of \nNI-SLN treatment, hepatocytes regained their \nnormal architecture, and the beneficial effect could be correlated with the reduction of SGOT and total bilirubin levels. \nTherefore, NI-SLN was found to be \nuseful for the enhancement of bioavailability and exhibited profound \nantidiabetic activity in rats. The results of the study suggested that \nNI-SLN exerted better improvement in glucose levels, lipid profiles and organ \nprotection than pure NI and might have some beneficial effects in the \nmanagement of diabetic patients.","PeriodicalId":19875,"journal":{"name":"Pharmacology & Pharmacy","volume":"100 1","pages":"457-471"},"PeriodicalIF":0.0000,"publicationDate":"2018-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Preparation and Antidiabetic Effect of Orally Administered Nifedipine‐Loaded Solid Lipid Nanoparticles in Fructose-Induced Diabetic Rats\",\"authors\":\"Sabarni Sarker, Md. Ashraf Ali, R. Barman, Shuji Noguchi, Y. Iwao, S. Itai, M. I. I. Wahed\",\"doi\":\"10.4236/PP.2018.910035\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The use of Nifedipine (NI), a dihydropyridine \\ncalcium channel blocker, is limited due to its \\npoor aqueous solubility. However, NI loaded solid-lipid nanoparticles (NI-SLN) \\nare known to exhibit suitable pharmacokinetic properties and good \\nbiocompatibility. The present investigation was designed to evaluate the \\neffects of NI-SLN on glucose homeostasis, lipid metabolism and liver function \\nin fructose-induced diabetic rats. NI-SLN was prepared by high pressure \\nhomogenization technique followed by lyophilization with trehalose as \\ncryoprotectant. Diabetes was induced into rats by the administration of \\nfructose (10%) in drinking water for six weeks. After induction of diabetes, \\nrats were divided into four groups for the oral ingestion of NI, NI-SLN and/or \\nvehicles and their effects on blood glucose levels, oral glucose tolerance test \\n(OGTT), lipid profile, biochemical parameters, electrolytes and histopathology \\nwere observed. Single dose administration and treatment with NI-SLN showed \\nsignificant glucose lowering efficacy in fructose-induced diabetic rats. \\nAlthough NI and NI-SLN did not alter the fasting blood glucose level in normal \\nrats, diabetic rats treated with NI-SLN resulted in significant reduction in \\nglucose level for 24 hr. In OGTT, NI-SLN exhibited significant \\nantihyperglycemic activity in both normal and diabetic rats. So, NI-SLN has \\nbetter glucose lowering efficacy than that of pure NI in diabetic rats. The \\nsurvival rates in rats among the treatment groups were 100%. Treatment with \\nNI-SLN significantly improved lipid profiles than NI alone and the effect was \\ndose-dependent. Administration of NI-SLN significantly reduced uric acid, \\ncreatinine levels and maintained a good cationic balance. After two weeks of \\nNI-SLN treatment, hepatocytes regained their \\nnormal architecture, and the beneficial effect could be correlated with the reduction of SGOT and total bilirubin levels. \\nTherefore, NI-SLN was found to be \\nuseful for the enhancement of bioavailability and exhibited profound \\nantidiabetic activity in rats. The results of the study suggested that \\nNI-SLN exerted better improvement in glucose levels, lipid profiles and organ \\nprotection than pure NI and might have some beneficial effects in the \\nmanagement of diabetic patients.\",\"PeriodicalId\":19875,\"journal\":{\"name\":\"Pharmacology & Pharmacy\",\"volume\":\"100 1\",\"pages\":\"457-471\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-10-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacology & Pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4236/PP.2018.910035\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology & Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4236/PP.2018.910035","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Preparation and Antidiabetic Effect of Orally Administered Nifedipine‐Loaded Solid Lipid Nanoparticles in Fructose-Induced Diabetic Rats
The use of Nifedipine (NI), a dihydropyridine
calcium channel blocker, is limited due to its
poor aqueous solubility. However, NI loaded solid-lipid nanoparticles (NI-SLN)
are known to exhibit suitable pharmacokinetic properties and good
biocompatibility. The present investigation was designed to evaluate the
effects of NI-SLN on glucose homeostasis, lipid metabolism and liver function
in fructose-induced diabetic rats. NI-SLN was prepared by high pressure
homogenization technique followed by lyophilization with trehalose as
cryoprotectant. Diabetes was induced into rats by the administration of
fructose (10%) in drinking water for six weeks. After induction of diabetes,
rats were divided into four groups for the oral ingestion of NI, NI-SLN and/or
vehicles and their effects on blood glucose levels, oral glucose tolerance test
(OGTT), lipid profile, biochemical parameters, electrolytes and histopathology
were observed. Single dose administration and treatment with NI-SLN showed
significant glucose lowering efficacy in fructose-induced diabetic rats.
Although NI and NI-SLN did not alter the fasting blood glucose level in normal
rats, diabetic rats treated with NI-SLN resulted in significant reduction in
glucose level for 24 hr. In OGTT, NI-SLN exhibited significant
antihyperglycemic activity in both normal and diabetic rats. So, NI-SLN has
better glucose lowering efficacy than that of pure NI in diabetic rats. The
survival rates in rats among the treatment groups were 100%. Treatment with
NI-SLN significantly improved lipid profiles than NI alone and the effect was
dose-dependent. Administration of NI-SLN significantly reduced uric acid,
creatinine levels and maintained a good cationic balance. After two weeks of
NI-SLN treatment, hepatocytes regained their
normal architecture, and the beneficial effect could be correlated with the reduction of SGOT and total bilirubin levels.
Therefore, NI-SLN was found to be
useful for the enhancement of bioavailability and exhibited profound
antidiabetic activity in rats. The results of the study suggested that
NI-SLN exerted better improvement in glucose levels, lipid profiles and organ
protection than pure NI and might have some beneficial effects in the
management of diabetic patients.